Late Mortality in TAVR Is Mainly Due to Non-Cardiac Causes

Transcatheter aortic valve replacement (TAVR) has revolutionized the management of high-risk patients with severe aortic stenosis. However, survival after the procedure and severe complications have been assessed in relatively small populations with limited follow-up.   This article reports long-term clinical results in the FRANCE-2 (FRench Aortic National CoreValve and Edwards) registry.   The FRANCE-2 registry<a href="https://solaci.org/en/2016/10/05/late-mortality-in-tavr-is-mainly-due-to-non-cardiac-causes/" title="Read more" >...</a>

Seguridad de combinar los nuevos anticoagulantes y la doble antiagregación

Cost-Effectiveness of Left Atrial Appendage Closure and the New Anticoagulants vs. Warfarin in Atrial Fibrillation

Original Title: Time to Cost-Effectiveness Following Stroke Reduction Strategies in AF Warfarin vs. NOACs vs. LAA Closure. Reference: Vivek Y. Reddy et al. J Am Coll Cardiol. 2015;66(24):2728-2739. Left atrial appendage closure and the new anticoagulants (NOACs) have emerged as safe and effective alternatives to warfarin for stroke in patients with non-valvular atrial fibrillation. This analysis<a href="https://solaci.org/en/2015/12/23/cost-effectiveness-of-left-atrial-appendage-closure-and-the-new-anticoagulants-vs-warfarin-in-atrial-fibrillation/" title="Read more" >...</a>

TAVR: Regression of Left Ventricular Hypertrophy Decreases Re-hospitalization

Original title: Early Regression of Severe Left Ventricular Hypertrophy After Transcatheter Aortic Valve Replacement Is Associated with Decreased Hospitalization. Reference: Brian Lindman, et al. JACC Cardiovasc Interv 2014;7:662-73.   Left ventricular hypertrophy, defined by the increase of left ventricular mass, has long been associated to increased morbi-mortality in the context of different heart conditions. LV hypertrophy regression might<a href="https://solaci.org/en/2014/08/05/tavr-regression-of-left-ventricular-hypertrophy-decreases-re-hospitalization/" title="Read more" >...</a>

The complete Left Bundle Branch Block after TAVI is not associated with increased mortality at 12 months

Original title: Impact of New-Onset Persistent Left Bundle Branch Block on late Clinical Outcomes in Patients Undergoing Trancatheter Aortic Valve implantation with a Balloon –Expandable Valve. Reference: Urena Marina, el al. JACC Cardiovasc Interv. 2014 Feb;7(2):128-36. Percutaneous aortic valve implantation brings, sometimes the presence of permanent left bundle branch block (LBBB) that has been associated in some series<a href="https://solaci.org/en/2014/03/18/the-complete-left-bundle-branch-block-after-tavi-is-not-associated-with-increased-mortality-at-12-months/" title="Read more" >...</a>

Strategies for treating left coronary trunk restenosis.

Original title: Clinical and Procedural Predictors of Suboptimal Outcome After the Treatment of Drug-Eluting Stent Restenosis in the Unprotected Distal Left Main Stem The Milan and New-Tokyo (MITO) Registry. Reference: Circ Cardiovasc Interv. 2012;5: 491-498 We have very little data on the percutaneous treatment of restenosis of an unprotected LMCA.  The aim of this study was to evaluate<a href="https://solaci.org/en/2012/12/06/strategies-for-treating-left-coronary-trunk-restenosis/" title="Read more" >...</a>

ULTIMATE III: Use of IVUS for Coronary De Novo Lesion Drug Coated Balloon Angioplasty

Percutaneous coronary intervention (PCI) with drug eluting stents (DES) can present limitations, especially in the form of stent thrombosis or instent restenosis (ISR). These findings have furthered the development of drub coated balloons (DCB). The safety and efficacy of DCB have already been shown in the context of ISR and de novo small vessel coronary<a href="https://solaci.org/en/2024/07/12/ultimate-iii-use-of-ivus-for-coronary-de-novo-lesion-drug-coated-balloon-angioplasty/" title="Read more" >...</a>

Events in CAD Patients Who Refused or Were Ineligible for CABG

When deciding on the optimal coronary artery revascularization treatment of coronary artery disease (CAD) patients, physicians normally assessed clinical presentation, surgical risk, survival expectation, and the likelihood of a better quality of life. Decisions are made after careful consideration, by the Heart Team, who will ponder options such as coronary artery bypass graft (CABG), percutaneous<a href="https://solaci.org/en/2024/06/26/events-in-cad-patients-who-refused-or-were-ineligible-for-cabg/" title="Read more" >...</a>

La estrategia invasiva en pacientes frágiles es segura

Complex PCI in Octogenarian

The octogenarian population has already reached 137 million and continues to grow. It is estimated to triple by 2050.  This increase represents a big challenge, seeing as these patients are often more fragile, present more complex coronary artery disease and multiple comorbidities. This generally requires two or more procedures and more experience both from operators<a href="https://solaci.org/en/2024/06/18/complex-pci-in-octogenarian/" title="Read more" >...</a>

Coronary Angioplasty with Sirolimus Eluting Stents

At present, most percutaneous coronary intervention procedures (PCI) are done with drug eluting stents (DES). However, drug coated balloons (DCB) have shown benefits in restenosis and small vessel de novo lesions.  Intravascular ultrasound (IVUS) has been shown effective in left main PCI and complex procedures, even though there is little infomration on its use for<a href="https://solaci.org/en/2024/06/12/coronary-angioplasty-with-sirolimus-eluting-stents/" title="Read more" >...</a>

Dietas bajas en carbohidratos y progresión de la calcificación coronaria

REPLICA-EPICA 18 Registry: Using IVL in Calcified Coronary Lesions

The presence of calcification in the coronary arteries (CAC) remains the main challenge in the percutaneous treatment of these lesions. Various studies have demonstrated the association of CAC with unfavorable long-term outcomes. Intravascular lithotripsy (IVL) has emerged as an effective tool for fracturing calcified plaques. Studies evaluating this strategy have shown high device success rates,<a href="https://solaci.org/en/2024/05/28/replica-epica-18-registry-using-ivl-in-calcified-coronary-lesions/" title="Read more" >...</a>